GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » Shares Outstanding (EOP)

Enveric Biosciences (STU:SLZ) Shares Outstanding (EOP) : 0.69 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Enveric Biosciences's shares outstanding for the quarter that ended in Dec. 2024 was 0.69 Mil.

Enveric Biosciences's quarterly shares outstanding increased from Sep. 2024 (0.60 Mil) to Dec. 2024 (0.69 Mil). It means Enveric Biosciences issued new shares from Sep. 2024 to Dec. 2024 .

Enveric Biosciences's annual shares outstanding increased from Dec. 2023 (0.18 Mil) to Dec. 2024 (0.69 Mil). It means Enveric Biosciences issued new shares from Dec. 2023 to Dec. 2024 .


Enveric Biosciences Shares Outstanding (EOP) Historical Data

The historical data trend for Enveric Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Shares Outstanding (EOP) Chart

Enveric Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.04 0.14 0.18 0.69

Enveric Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.49 0.53 0.60 0.69

Competitive Comparison of Enveric Biosciences's Shares Outstanding (EOP)

For the Biotechnology subindustry, Enveric Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Shares Outstanding (EOP) falls into.


;
;

Enveric Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Enveric Biosciences  (STU:SLZ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Enveric Biosciences Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.